Colorectal Cancer

Moving on to the second patient scenario, panelists elucidate the value of ctDNA in patients with triple-negative breast cancer.

Investigators found that patients with non–gain-of-function TP53-mutant right-sided metastatic colorectal cancer and gain-of-function TP53-mutant left-sided tumors had poorer survival vs their counterparts.

Data from the PARADIGM trial that were presented at 2022 ASCO demonstrated that panitumumab plus FOLFOX should be standard of care for patients with left-sided, RAS wild-type colorectal cancer, according to Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, discussed how data from clinical trials examining different targeted strategies in colorectal cancer will transform the way in which patients with this malignancy are seen and treated.

At 2022 ASCO, Tanios S. Bekaii-Saab, MD, talks about how data from the ongoing MOUNTAINEER trial investigating trastuzumab plus tucatinib in HER2-positive metastatic colorectal cancer and other similar trials may impact the standard of care going forward.

In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.

Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.

Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.

Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.

Development on CYAD-101 as a treatment for patients with refractory/metastatic colorectal cancer continues after the FDA has lifted a clinical hold on the phase 1b CYAD-101-002 trial.

At 2022 ASCO, Tanios S. Bekaii-Saab, MD, reviews the MOUNTAINEER trial of trastuzumab plus tucatinib for HER2-positive metastatic colorectal cancer and foreshadows how an approved regimen may help improve outcomes in this patient population.

Cornelis J. A. Punt, MD, PhD, spoke about the phase 3 CAIRO5 trial of bevacizumab plus either FOLFOXIRI or FOLFOX/FOLFIRI for patients with initially unresectable colorectal liver metastases.

Serial postoperative ctDNA analysis could be a useful tool in guiding treatment decisions and improving care for patients with stage III colorectal cancer.

Shared insight on the potential roles of ctDNA and MRD testing in the monitoring and treatment of patients with colorectal cancer.

Centering discussion on a patient scenario of stage II colorectal cancer, expert oncologists consider how ctDNA may inform use of adjuvant chemotherapy in this setting.

Patients with mismatch repair deficient and/or microsatellite instability–high locally advanced colorectal cancer appear to derive promising benefit from treatment with neoadjuvant immune checkpoint inhibitors.

The needle might be further pushed forward for precision medicine through exploration of novel proteins such as CDC37 and MAOB in patients with metastatic colorectal cancer.

MAOB and CDC37 gene expression appear to be 2 new promising targets in advanced colorectal cancer, according to Heinz-Josef Lenz, MD.

Patients with previously treated HER2-positive metastatic colorectal cancer experienced durable responses following treatment with tucatinib in combination with trastuzumab.

Richard Kim, MD, highlights future research efforts examining immunotherapy/chemotherapy combinations for patients with metastatic colorectal cancer.

Richard Kim, MD, discussed key findings of the phase 1b KEYNOTE-651 trial, examining pembrolizumab plus standard chemotherapy in patients with microsatellite-stable or mismatch repair–proficient colorectal cancer.

During the 2022 American Society of Clinical Oncology Annual Meeting, Richard Kim, MD, discusses the rationale for the phase 1b KEYNOTE-651 trial examining pembrolizumab plus chemotherapy in metastatic colorectal cancer.

Adding irinotecan to chemotherapy plus panitumumab for treatment of metastatic colorectal cancer did not result in a significant impact on efficacy.

In patients with colorectal cancer and synchronous unresectable metastases, resection of the primary tumor before systemic therapy did not result in an extension of overall survival.

Bevacizumab plus FOLFOXIRI was superior to bevacizumab plus FOLFOX or FOLFIRI in terms of efficacy but was more toxic in certain patients with initially unresectable colorectal cancer liver metastases.